Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.52 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17155 | 0.95 | CYP4F2 (0.56) | CYP4F2CYP4A11NPSR1CETPLMNA | |
| SCHEMBL17857 | 0.93 | CYP4F2 (0.55) | CYP4F2CYP4A11NPSR1CETPLMNA | |
| SCHEMBL2285823 | 0.91 | — | — | |
| SCHEMBL5271625 | 0.83 | CYP4F2 (0.58) | CYP4F2CYP4A11NPSR1CETPLMNA | |
| SCHEMBL3952155 | 0.82 | CYP4F2 (0.56) | CYP4F2CYP4A11NPSR1LMNAP2RX7 | |
| SCHEMBL16310454 | 0.81 | OPRM1 (0.42) | CYP4F2CYP4A11NPSR1LMNAKMT2A | |
| SCHEMBL21963873 | 0.81 | CYP4F2 (0.40) | CYP4F2CYP4A11NPSR1LMNAMAPT | |
| SCHEMBL16508916 | 0.81 | CYP3A4 (0.40) | CYP4F2CYP4A11NPSR1MEN1CYP3A4 | |
| SCHEMBL2289682 | 0.80 | SMN1; SMN2 (0.44) | LMNAMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL15572190 | 0.80 | CYP4F2 (0.50) | CYP4F2CYP4A11NPSR1LMNAP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025056065-A1 | CHEMOKINE RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION, AND USE | 上海医药集团股份有限公司 | 2025-03-20 | — | — | WO | disclosed |
| CN-119638669-A | Chemokine receptor antagonist, pharmaceutical composition and application | 上海医药集团股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20230150989-A1 | HERBICIDAL MALONAMIDES | BASF SE (DE) | 2023-05-18 | — | — | US | disclosed |
| US-20180022732-A1 | COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO RET | BLUEPRINT MEDICINES CORPORATION | 2018-01-25 | — | — | US | disclosed |
| US-20180022736-A1 | CARBOXYLIC ACID COMPOUND, METHOD FOR PREPARATION THEREOF, AND USE THEREOF | InventisBio Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
| US-9809580-B2 | Carboxylic acid compound, method for preparation thereof, and use thereof | INVENTISBIO SHANGHAI LTD. (CN) | 2017-11-07 | — | — | US | disclosed |
| US-20170233376-A1 | CARBOXYLIC ACID COMPOUND, METHOD FOR PREPARATION THEREOF, AND USE THEREOF | InventisBio Co., Ltd. (CN) | 2017-08-17 | — | — | US | disclosed |
| WO-2012025857-A1 | CYCLOALKYL METHOXYBENZYL PHENYL PYRAN DERIVATIVES AS SODIUM DEPENDENT GLUCOSE CO TRANSPORTER (SGLT2) INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012025857-A1 | CYCLOALKYL METHOXYBENZYL PHENYL PYRAN DERIVATIVES AS SODIUM DEPENDENT GLUCOSE CO TRANSPORTER (SGLT2) INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2012-03-01 | — | — | WO | disclosed |
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-01 | — | — | US | disclosed |
| EP-2179651-A1 | PLANT DISEASE CONTROL AGENT, AND PLANT DISEASE CONTROL METHOD | Sumitomo Chemical Company, Limited (JP) | 2010-04-28 | — | — | EP | disclosed |
| EP-2174931-A1 | AMIDE COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-20100069499-A1 | AMIDE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100056640-A1 | AMIDE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2151431-A1 | AMIDE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2010-02-10 | — | — | EP | disclosed |
| EP-2143709-A1 | AMIDE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2010-01-13 | — | — | EP | disclosed |
| US-7572783-B2 | Obesity; N-(1-benzyl-piperidin-4-yl)-2-(2,5-dioxo-7-phenoxy-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl)-3-methyl-butyramide; modulators of ghrelin receptor (GHSR) | AMGEN INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1784390-A2 | SUBSTITUTED BENZOFUSED HETEROCYCLES | Amgen Inc. (US) | 2007-05-16 | — | — | EP | disclosed |
| US-20060199796-A1 | Substituted benzofused heterocycles | AMGEN INC. (US) | 2006-09-07 | — | — | US | disclosed |
| WO-2006020959-A2 | SUBSTITUTED BENZOFUSED HETEROCYCLES | AMGEN INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056640-A1 | AMIDE COMPOUND AND USE THEREOF | NAT1, AGXT, HAX1 | CYP4F2 1238/4885CYP4A11 1152/4885NPSR1 3041/4885 |
| US-20100069499-A1 | AMIDE COMPOUND AND USE THEREOF | CBR1, CBR3, GBA1 | CYP4F2 403/4885CYP4A11 75/4885NPSR1 1735/4885 |
| US-20180022732-A1 | COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO RET | RET, EYA2, HRAS | CYP4F2 4133/4885CYP4A11 4343/4885NPSR1 3401/4885 |
| US-20170233376-A1 | CARBOXYLIC ACID COMPOUND, METHOD FOR PREPARATION THEREOF, AND USE THEREOF | CA7, CYP2C9, CA9 | CYP4F2 46/4885CYP4A11 24/4885NPSR1 1344/4885 |
| US-20230150989-A1 | HERBICIDAL MALONAMIDES | DDT, DHRS9, CA9 | CYP4F2 386/4885CYP4A11 671/4885NPSR1 3806/4885 |
| US-20060199796-A1 | Substituted benzofused heterocycles | GPR119, SDHA, OGDH | CYP4F2 15/4885CYP4A11 312/4885NPSR1 489/4885 |
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | ESR2, IGF1R, ESRRA | CYP4F2 2242/4885CYP4A11 283/4885NPSR1 2645/4885 |
| US-20180022736-A1 | CARBOXYLIC ACID COMPOUND, METHOD FOR PREPARATION THEREOF, AND USE THEREOF | CA7, CYP2C9, CA9 | CYP4F2 46/4885CYP4A11 24/4885NPSR1 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.